MCID: GLC008
MIFTS: 44

Glucose Metabolism Disease

Categories: Metabolic diseases

Aliases & Classifications for Glucose Metabolism Disease

MalaCards integrated aliases for Glucose Metabolism Disease:

Name: Glucose Metabolism Disease 12 14
Glucose Metabolism Disorders 42 69
Disorder of Glucose Metabolism 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4194
MeSH 42 D044882
NCIt 47 C53655
SNOMED-CT 64 126877002
UMLS 69 C1257958

Summaries for Glucose Metabolism Disease

MalaCards based summary : Glucose Metabolism Disease, also known as glucose metabolism disorders, is related to achard thiers syndrome and chronic fungal otitis externa. An important gene associated with Glucose Metabolism Disease is INS (Insulin), and among its related pathways/superpathways are Metabolism of proteins and Developmental Biology. The drugs Adalimumab and Dimethyl fumarate have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and endothelial, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Glucose Metabolism Disease

Diseases related to Glucose Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
id Related Disease Score Top Affiliating Genes
1 achard thiers syndrome 11.1 ADIPOQ PPARG
2 chronic fungal otitis externa 11.1 CRP INS
3 cryptogenic organizing pneumonia 11.1 ALB CRP TRPV1
4 myh-9 related disease 11.1 INS LEP SLC2A4
5 retinitis pigmentosa 17 11.1 ACE ALB INS
6 cataract, autosomal dominant congenital 4 11.1 ACE INS PPARG
7 oxyphilic adenoma 11.1 IGF1 IRS1
8 hypothyroidism due to iodide transport defect 11.1 ACE REN
9 non-congenital cyst of kidney 11.1 ACE ALB REN
10 lissencephaly 11.1 INS LEP PPARG
11 acquired hypoprothrombinemia 11.1 ADIPOQ LEP
12 hyperinsulinemic hypoglycemia, familial, 4 11.1 ADIPOQ INS PPARG
13 mucinoses 11.1 ADIPOQ INS LEP
14 fetal parvovirus syndrome 11.1 IGF1 INS LEP
15 adenocarcinoma 11.1 ACE ALB REN
16 acute insulin response 11.1 CRP GCG INS
17 myopia 11.1 ACE ALB REN
18 glomerulosclerosis, focal segmental, 1 11.1 IGF1 INS IRS1
19 mediastinum leiomyoma 11.1 ALB CRP LEP
20 bladder sarcoma 11.1 ALB IGF1 LEP
21 ischemic heart disease 11.1 ACE ALB CRP
22 allergic bronchopulmonary aspergillosis 11.1 ALB CRP IER3IP1
23 cardiomyopathy, dilated, 1jj 11.1 GCG INS
24 broad ligament malignant neoplasm 11.1 ACE ALB REN
25 spastic entropion 11.1 ALB CRP IER3IP1
26 porokeratosis 11.1 IGF1 INS LEP
27 choroiditis 11.1 ACE ALB CRP
28 exophthalmic ophthalmoplegia 11.1 ADIPOQ ALB LEP
29 idiopathic juxtafoveal retinal telangiectasia 11.1 ACE ADIPOQ INS PPARG
30 nonsyndromic hereditary sensorineural hearing loss 11.1 ADIPOQ INS LEP PPARG
31 melorheostosis 11.1 ACE ALB CRP
32 brain glioblastoma multiforme 11.1 CRP IER3IP1 TRPV1
33 intramuscular hemangioma 11.1 ALB CRP INS LEP
34 pancreatic acinar cell adenocarcinoma 11.1 INS PSMD9 TRPV1
35 vernal conjunctivitis 11.0 ALB IGF1 INS PSMD9
36 lacrimal system cancer 11.0 ACE ALB CRP TRPV1
37 peripheral degeneration of cornea 11.0 GCG GIP INS
38 keratosis 11.0 DPP4 IER3IP1 PSMD9
39 primary hyperoxaluria 11.0 ACE REN
40 mature gastric teratoma 11.0 ADIPOQ INS LEP PPARG
41 citrullinemia, adult-onset type ii 11.0 ACE ALB IGF1 INS
42 ovarian clear cell malignant adenofibroma 11.0 ADIPOQ CRP INS
43 listeriosis 11.0 ACE ADIPOQ PSMD9 REN
44 selenium poisoning 11.0 IGF1 INS
45 perinatal necrotizing enterocolitis 11.0 ADIPOQ ALB LEP
46 wernicke-korsakoff syndrome 11.0 ALB REN
47 ragweed sensitivity 11.0 ADIPOQ CRP PPARG
48 endometrial clear cell adenocarcinoma 11.0 ALB CRP GCG TRPV1
49 cystinosis 11.0 ACE ALB CRP REN
50 lymphoma 11.0 ACE ALB TRPV1

Graphical network of the top 20 diseases related to Glucose Metabolism Disease:



Diseases related to Glucose Metabolism Disease

Symptoms & Phenotypes for Glucose Metabolism Disease

MGI Mouse Phenotypes related to Glucose Metabolism Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 REN SLC2A4 SLC5A2 TRPV1 ACE ADIPOQ
2 growth/size/body region MP:0005378 10.28 TRPV1 ACE ADIPOQ BACE1 DPP4 GIP
3 cardiovascular system MP:0005385 10.2 ACE ADIPOQ CRP IGF1 INS IRS1
4 adipose tissue MP:0005375 10.18 ACE ADIPOQ IGF1 INS IRS1 LEP
5 endocrine/exocrine gland MP:0005379 10.13 DPP4 IGF1 INS IRS1 LEP PPARG
6 immune system MP:0005387 10.13 LEP PPARG REN SLC2A4 SLC5A2 TRPV1
7 liver/biliary system MP:0005370 9.91 ACE ADIPOQ ALB INS IRS1 LEP
8 muscle MP:0005369 9.85 ADIPOQ ALB BACE1 IGF1 INS IRS1
9 neoplasm MP:0002006 9.5 ACE ADIPOQ ALB IGF1 LEP PPARG
10 renal/urinary system MP:0005367 9.32 ACE ADIPOQ ALB IGF1 INS LEP

Drugs & Therapeutics for Glucose Metabolism Disease

Drugs for Glucose Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1220)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
2
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
3
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
4
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
5
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 160337-95-1
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
7
Candesartan Approved Phase 4,Phase 3,Phase 2 139481-59-7 2541
8
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
9
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 1 128-13-2 31401
10
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
11 Parecoxib Approved Phase 4 198470-84-7
12
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
13
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 56180-94-0 441184
14
Glipizide Approved Phase 4,Phase 3,Phase 2,Phase 1 29094-61-9 3478
15
Fluoxetine Approved, Vet_approved Phase 4,Early Phase 1 54910-89-3 3386
16
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
17
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
18
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1 10102-43-9 145068
19
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142387-99-3, 95635-55-5 56959
20
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
21
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
22
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
23
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
24
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
25
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
26
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 122320-73-4 77999
27
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
28
Cilostazol Approved Phase 4 73963-72-1 2754
29
Atenolol Approved Phase 4 29122-68-7 2249
30
Amlodipine Approved Phase 4,Phase 3,Phase 1 88150-42-9 2162
31
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
32
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
33
Orlistat Approved, Investigational Phase 4,Phase 2,Phase 1 96829-58-2 3034010
34
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-28-2 5757
35
Norethindrone Approved Phase 4,Phase 1 68-22-4 6230
36
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 133107-64-9
37
Febuxostat Approved Phase 4 144060-53-7 134018
38
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
39
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
40
Ticlopidine Approved Phase 4,Phase 3,Phase 2 55142-85-3 5472
41
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
42
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
43
Alprostadil Approved, Investigational Phase 4 745-65-3 149351
44
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
45
Ramipril Approved Phase 4,Phase 3,Early Phase 1 87333-19-5 5362129
46
Ezetimibe Approved Phase 4,Phase 3,Phase 2 163222-33-1 150311
47
Sertraline Approved Phase 4 79617-96-2 68617
48
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1 116094-23-6 16132418
49
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1 169148-63-4 5311023
50
Thrombin Approved Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 9776)

id Name Status NCT ID Phase Drugs
1 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
2 The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
3 Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus Unknown status NCT00298844 Phase 4
4 Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study Unknown status NCT01800734 Phase 4
5 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
6 Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
7 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
8 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
9 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
10 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
11 A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care Unknown status NCT00939250 Phase 4
12 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
13 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
14 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
15 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
16 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
17 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
18 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
19 Effect of Dapagliflozine on Systemic and Renal Endothelial Function Unknown status NCT02501616 Phase 4 Metformin;Dapagliflozin
20 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
21 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
22 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
23 Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT Unknown status NCT01021930 Phase 4
24 Japanese Primary Prevention Project With Aspirin Unknown status NCT00225849 Phase 4 Aspirin
25 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
26 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
27 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
28 Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes Unknown status NCT00925119 Phase 4 Atenolol
29 Korean AMADEUS Study Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
30 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
31 Intensity of Exercise and Glucose Metabolism Unknown status NCT01649219 Phase 4
32 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
33 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
34 Oxidative Stress Lowering Effect of Simvastatin and Atorvastatin. Unknown status NCT00404599 Phase 4 atrorvastatin 10mg;simvastatin 40mg
35 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
36 Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
37 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
38 Organization Program of DiabEtes INsulIN ManaGement Unknown status NCT01338376 Phase 4 Scilin®M30
39 The Effect of Uric Acid Lowering in Type 1 Diabetes Unknown status NCT02344602 Phase 4 Febuxostat
40 Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4 Curcumin
41 Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel Unknown status NCT01643031 Phase 4 Ticagrelor;Continued clopidogrel
42 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
43 Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
44 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
45 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity Unknown status NCT01736202 Phase 4
46 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4 Cholecalciferol;placebo
47 Improving Function, Quality of Life, Glycemia in Diabetics With Dementia Unknown status NCT00792662 Phase 4 Methylphenidate;Placebo
48 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
49 Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
50 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)

Search NIH Clinical Center for Glucose Metabolism Disease

Cochrane evidence based reviews: glucose metabolism disorders

Genetic Tests for Glucose Metabolism Disease

Anatomical Context for Glucose Metabolism Disease

MalaCards organs/tissues related to Glucose Metabolism Disease:

39
Heart, Kidney, Endothelial, Liver, Brain, Testes, Bone

Publications for Glucose Metabolism Disease

Variations for Glucose Metabolism Disease

Expression for Glucose Metabolism Disease

Search GEO for disease gene expression data for Glucose Metabolism Disease.

Pathways for Glucose Metabolism Disease

Pathways related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 ACE BACE1 DPP4 GCG GIP IAPP
2
Show member pathways
13.39 ADIPOQ IAPP INS IRS1 LEP PPARG
3
Show member pathways
12.67 ADIPOQ INS IRS1 LEP SLC2A4
4 12.38 ADIPOQ GCG INS IRS1 PPARG SLC2A4
5
Show member pathways
12.29 ALB GCG GIP INS
6
Show member pathways
12.28 ADIPOQ IGF1 INS IRS1 LEP PPARG
7
Show member pathways
12.1 INS IRS1 LEP SLC2A4
8
Show member pathways
12.01 ADIPOQ IGF1 INS IRS1 PPARG
9
Show member pathways
11.98 IGF1 INS IRS1 SLC2A4
10 11.82 ADIPOQ IGF1 INS IRS1 LEP PPARG
11
Show member pathways
11.76 ADIPOQ INS IRS1 SLC2A4
12 11.72 ADIPOQ IGF1 INS LEP PPARG SLC2A4
13 11.6 ADIPOQ IRS1 LEP SLC2A4
14
Show member pathways
11.49 ACE DPP4 GCG GIP IGF1 INS
15 11.45 IRS1 LEP SLC2A4
16
Show member pathways
11.45 DPP4 GCG GIP LEP
17 11.42 INS IRS1 LEP
18 11.27 IGF1 INS IRS1
19 11.07 ADIPOQ LEP PPARG
20 10.7 ADIPOQ IRS1 LEP PPARG SLC2A4

GO Terms for Glucose Metabolism Disease

Cellular components related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ACE ADIPOQ ALB CRP DPP4 GCG
2 endoplasmic reticulum lumen GO:0005788 9.55 ALB BACE1 GCG GIP INS
3 extracellular space GO:0005615 9.36 ACE ADIPOQ ALB CRP GCG GIP

Biological processes related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.89 ALB BACE1 IAPP IGF1 INS
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.79 ADIPOQ IGF1 INS
3 response to nutrient GO:0007584 9.78 ADIPOQ LEP PPARG
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 IGF1 INS LEP
5 cellular response to insulin stimulus GO:0032869 9.76 ADIPOQ IRS1 PPARG SLC2A4
6 glucose metabolic process GO:0006006 9.75 ADIPOQ INS LEP
7 response to nutrient levels GO:0031667 9.73 ADIPOQ GIP LEP
8 regulation of blood pressure GO:0008217 9.73 ACE LEP PPARG REN
9 sensory perception of pain GO:0019233 9.72 GIP IAPP TRPV1
10 response to peptide hormone GO:0043434 9.71 GIP IRS1 TRPV1
11 regulation of insulin secretion GO:0050796 9.71 DPP4 GCG GIP LEP
12 response to lipid GO:0033993 9.65 GIP PPARG
13 positive regulation of MAPK cascade GO:0043410 9.65 IGF1 INS LEP
14 fatty acid oxidation GO:0019395 9.64 ADIPOQ PPARG
15 positive regulation of protein kinase B signaling GO:0051897 9.64 INS LEP
16 negative regulation of gluconeogenesis GO:0045721 9.63 ADIPOQ INS
17 insulin-like growth factor receptor signaling pathway GO:0048009 9.63 IGF1 IRS1
18 angiotensin maturation GO:0002003 9.61 ACE REN
19 negative regulation of lipid storage GO:0010888 9.59 CRP LEP
20 negative regulation of acute inflammatory response GO:0002674 9.57 INS PPARG
21 positive regulation of glycogen biosynthetic process GO:0045725 9.54 IGF1 INS IRS1
22 bone mineralization involved in bone maturation GO:0035630 9.52 IGF1 LEP
23 response to starvation GO:0042594 9.51 GIP PPARG
24 beta-amyloid metabolic process GO:0050435 9.5 ACE BACE1 REN
25 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.43 ADIPOQ CRP PPARG
26 positive regulation of insulin receptor signaling pathway GO:0046628 9.33 INS IRS1 LEP
27 positive regulation of protein kinase A signaling GO:0010739 9.3 ADIPOQ
28 positive regulation of glucose import GO:0046326 9.26 ADIPOQ IGF1 INS IRS1
29 glucose homeostasis GO:0042593 9.1 ADIPOQ INS IRS1 LEP PPARG SLC2A4
30 positive regulation of cell proliferation GO:0008284 10.02 DPP4 IGF1 INS IRS1 LEP

Molecular functions related to Glucose Metabolism Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.76 ADIPOQ ALB DPP4 GCG IAPP INS
2 receptor binding GO:0005102 9.73 ADIPOQ DPP4 GCG IAPP LEP REN
3 endopeptidase activity GO:0004175 9.58 ACE BACE1 REN
4 drug binding GO:0008144 9.54 ACE ALB PPARG
5 insulin receptor binding GO:0005158 9.5 IGF1 INS IRS1
6 insulin-like growth factor receptor binding GO:0005159 9.26 IGF1 INS IRS1 REN
7 hormone activity GO:0005179 9.17 ADIPOQ GCG GIP IAPP IGF1 INS

Sources for Glucose Metabolism Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....